Media stories about Opiant Pharmaceuticals (NASDAQ:OPNT) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 48.8490593294619 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
OPNT has been the subject of several recent analyst reports. TheStreet lowered shares of Opiant Pharmaceuticals from a “c+” rating to a “d+” rating in a report on Monday, December 11th. ValuEngine lowered shares of Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 27th.
Shares of Opiant Pharmaceuticals (OPNT) opened at $20.16 on Friday. Opiant Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $51.90. The firm has a market cap of $39.14, a P/E ratio of 48.00 and a beta of -0.38.
Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings results on Monday, December 4th. The technology company reported ($2.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($1.58). Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%. The company had revenue of $0.02 million for the quarter. equities research analysts predict that Opiant Pharmaceuticals will post 0.17 earnings per share for the current fiscal year.
In other news, major shareholder Geoffrey Wolf sold 34,938 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $22.67, for a total transaction of $792,044.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 63.82% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Opiant Pharmaceuticals (OPNT) Getting Somewhat Positive Media Coverage, Report Finds” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/11/opiant-pharmaceuticals-opnt-receives-daily-news-impact-score-of-0-06.html.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.